Companies / Industrials
EMR
Emerson Electric
Electrical Components & Equipment
Electrical Components & EquipmentAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health66
Growth47
Profitability67
Cash generation87
Balance sheet44
Dilution control83
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)7.1%Revenue growth (FY)5.4%Revenue CAGR (3y)7.8%Gross margin53.4%Operating margin—Net margin14.2%Free cash flow margin18.6%R&D / revenue4.3%Stock comp / revenue1.2%Net debt / operating cash flow2.80xCurrent ratio0.94Diluted share count change-0.8%
| Fiscal year ending | FY 2022-09 | FY 2023-09 | FY 2024-09 | FY 2025-09 | FY 2026-09 |
|---|---|---|---|---|---|
| Revenue | $13.8B | $15.2B | $17.5B | $18.0B | $19.0B |
| Gross profit | $6.3B | $7.4B | $8.9B | $9.5B | $10.1B |
| Net income | $3.2B | $13.2B | $2.0B | $2.3B | $2.7B |
| Operating cash flow | $2.9B | $637M | $3.3B | $3.1B | $4.0B |
| Capital expenditure | $299M | $363M | $419M | $431M | $443M |
| Free cash flow | $2.6B | $274M | $2.9B | $2.7B | $3.5B |
| R&D | $385M | $523M | $781M | $771M | $812M |
| Stock-based comp | $125M | $250M | $260M | $263M | $237M |
| Buybacks | $500M | $2.0B | $435M | $1.2B | $1.0B |
| Dividends | $1.2B | $1.2B | $1.2B | $1.2B | $1.2B |
| Cash | $1.8B | $8.1B | $3.6B | $1.5B | $1.8B |
| Total debt | $10.9B | $8.7B | $8.2B | $13.7B | $12.9B |
| Equity | $10.4B | $20.7B | $21.6B | $20.3B | $20.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.